It destroyed CD30+ tumor cell lines (L428 and L540) in vitro and cleared lymphoma in lymphoma-bearing mice, showing promising efficacy for the next phase of clinical trials [70]. This evidence concerns the gene TNFRSF8 and lymphoma.